This invention concerns the use of a compound of formula (I) ##STR00001## a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C.sub.1-6alkyl; C.sub.1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, mono- or di(C.sub.1-6alkyl)amino, aminocarbonyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl, C.sub.1-6alkyloxycarbonyl or C.sub.1-6alkyloxy; polyhaloC.sub.1-4alkyl; C.sub.1-4alkyloxy; cyano; amino; aminocarbonyl; mono- or di(C.sub.1-6alkyl)aminocarbonyl; C.sub.1-6alkyloxycarbonyl; C.sub.1-6alkylcarbonyloxy; H.sub.2N--S(.dbd.O).sub.2--; mono- or di(C.sub.1-6alkyl)amino-S(.dbd.O).sub.2; --C(.dbd.N--R.sup.x)NR.sup.yR.sup.z; Q is an optionally substituted carbocycle or an optionally substituted heterocycle; L is substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of diseases mediated through TNF-.alpha. and/or IL-12.